Zhenbin Qian

Title: Zhenbin Qian: Innovator in Liver Cirrhosis Diagnosis

Introduction

Zhenbin Qian is a notable inventor based in Shanghai, China. He has made significant contributions to the field of medical diagnostics, particularly in the prognosis and diagnosis of liver cirrhosis. His innovative work has the potential to improve patient outcomes and enhance the understanding of liver diseases.

Latest Patents

Zhenbin Qian holds a patent titled "Use of SAA1B/B homozygote in the prognosis and diagnosis of liver cirrhosis." This patent outlines the use of SAA1β/β (1.5/1.5) homozygote for the prognosis and diagnosis of liver cirrhosis. It provides methods for preparing a reagent for liver cirrhosis prognosis and diagnosis. The recognition of populations susceptible to liver cirrhosis can be achieved through the detection of human SAA1β/β homozygote and non-SAA1β/β homozygote using real-time fluorescence quantitative allele-specific PCR.

Career Highlights

Zhenbin Qian is currently associated with Diasys Diagnostic Systems (Shanghai) Co., Ltd. His work at this company focuses on advancing diagnostic technologies that can lead to better healthcare solutions. His expertise in the field has positioned him as a key player in medical innovation.

Collaborations

Zhenbin has collaborated with notable colleagues, including Rongfang Wang and Jun Wu. These partnerships have contributed to the development of innovative diagnostic methods and have enhanced the research capabilities within his field.

Conclusion

Zhenbin Qian's contributions to the diagnosis of liver cirrhosis through his patented innovations demonstrate his commitment to improving medical diagnostics. His work not only aids in the early detection of liver diseases but also paves the way for future advancements in healthcare.